Compare Goldman Sachs Group Inc (GS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs IDEXX Laboratories, Inc. — how do they compare? Goldman Sachs Group Inc trades at $897.79 (market cap $256.98B), while IDEXX Laboratories, Inc. trades at $516.84 (market cap $40.43B). The key difference: Goldman Sachs Group Inc is far larger — about 6.4× IDEXX Laboratories, Inc.'s market cap, and Goldman Sachs Group Inc pays a 2.27% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GS | IDXX | |
|---|---|---|
Market Cap | $256.98B | $40.43B |
Volume | 1,748,426 | 692,164 |
Sector | Financials | Health |
52-Week High | $1.15K | $766.68 |
52-Week Low | $744.60 | $504.70 |
Typical Hold Time | 101 Days | 46 Days |
Enterprise Value | $814.98B | $41.32B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $887.21, down 1.11% on the day, with a bearish technical signal despite strong fundamental performance. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $20.98 significantly exceeding expectations of $14.47. Revenue growth accelerated to $58.28 billion in 2025, while net income margin improved to 29.46%. Analyst consensus remains positive with a $1,130 price target, though technical indicators show selling pressure.
GS presents a compelling value opportunity with a P/E of 13.63 below industry averages, supported by robust earnings growth and a 31.68% net income margin. However, negative operating cash flow of -$45.15 billion in 2025 and bearish technical momentum create near-term headwinds. The stock's 18.33% ROE and dividend yield of approximately 0.56% provide shareholder returns, but investors should monitor cash flow trends and FICC business performance highlighted in recent management commentary.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
